26 Landsdowne Street
15 articles with Beam Therapeutics
Mr. Cooper was previously the chief financial officer and chief operating officer of Assembly Biosciences, a biotechnology company developing innovative therapeutics targeting hepatitis B virus.
Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday.
9/27/2019Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments.
Beam is a biotechnology company developing precision genetic medicines through base editing
Beam Therapeutics Appoints Financial Industry Veteran, Terry-Ann Burrell, as Chief Financial Officer
Beam Therapeutics announced the appointment of financial industry veteran, Terry-Ann Burrell, as chief financial officer.
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
Beam Therapeutics and Bio Palette Announce Exclusive License Agreements for Base Editing Technologies
Beam Therapeutics and Bio Palette announced an exclusive cross-license agreement around each companies’ base editing intellectual property.
5/31/2019Both companies said they plan to work together in order to strengthen their competitive positions.
Beam Therapeutics announced that John Evans, chief executive officer, will present a company overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 9:30 a.m. ET.
5/17/2019Biopharma companies add new leaders to executive roles and boards of directors.
Today announced multiple leadership appointments, strengthening the company’s management team.
Beam Therapeutics Presents Data on Multiplex Base Editing for Engineered CAR-T Cells at American Society of Gene and Cell Therapy 22nd Annual Meeting
Beam Therapeutics announced the presentation of preclinical data from the company’s base editing platform at the American Society of Gene and Cell Therapy 22nd Annual Meeting being held April 29 – May 2, 2019 in Washington, D.C.
Beam Therapeutics Secures $135 Million in Series B Financing to Advance Base Editing Platform and Expand Pipeline of Precision Genetic Medicines
Beam Therapeutics today announced the successful completion of a $135 million Series B financing.
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.